Schizophrenia Research
Volume 100, Issue 1 , Pages 39-52 , March 2008

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study

  • Marvin S. Swartz

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC, United States
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, DUMC Box 3173, Durham, NC 27710, United States. Tel.: +1 919 684 8676; fax: +1 919 681 7504.
    • ,
  • H. Ryan Wagner

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC, United States
    • ,
  • Jeffrey W. Swanson

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC, United States
    • ,
  • T. Scott Stroup

      Affiliations

    • Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, NC, United States
    • ,
  • Joseph P. McEvoy

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC, United States
    • ,
  • Fred Reimherr

      Affiliations

    • Department of Psychiatry, University of Utah Medical Center, Salt Lake City, UT, United States
    • ,
  • Del D. Miller

      Affiliations

    • Department of Psychiatry, University of Iowa School of Medicine, Iowa City, IA, United States
    • ,
  • Mark McGee

      Affiliations

    • Appalachian Behavioral Healthcare System, Athens OH, United States
    • ,
  • Ahsan Khan

      Affiliations

    • Psychiatric Research Institute, Wichita KS, United States
    • ,
  • Jose M. Canive

      Affiliations

    • Department of Psychiatry, Albuquerque Veteran’s Administration Medical Center and the University of New Mexico, Albequerque, NM, United States
    • ,
  • Sonia M. Davis

      Affiliations

    • Quintiles Inc., Research Triangle Park, NC, United States
    • ,
  • John K. Hsiao

      Affiliations

    • Division of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health, Bethesda, United States
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, United States
    • ,
  • for the CATIE Investigators

      Affiliations

    • The CATIE Investigators are listed in the Acknowledgements.

Received 22 October 2007 ,Revised 15 November 2007 ,Accepted 20 November 2007.

References 

  1. Abram K, Teplin L. Co-occurring disorders among mentally ill jail detainees: implications for public policy. Am. Psychol. 1991;46:1036–1044
  2. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992;6:201–208
  3. Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin. Psychol. Rev. 2000;20:207–234
  4. Buckley PF. New antipsychotic agents: emerging clinical profiles. J. Clin. Psychiatry. 1999;60:12–17
  5. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr. Res. 2001;48:69–82
  6. Cournos F, Empfield M, Horwath E, McKinnon K, Meyer I, Schrage H, et al. HIV prevalence among patients admitted to two psychiatric hospitals. Am. J. Psychiatry. 1991;148:1225–1229
  7. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr. Bull. 2003;29:73–80
  8. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999;35:S93–S100
  9. Drake R, Osher FC, Noordsy DL, Hurlbut SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 1990;16:57–67
  10. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. 2000;26:441–449
  11. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996;
  12. Goodman LA, Salyers MP, Mueser KT, Rosenberg SD, Swartz M, Essock SM, et al. Recent victimization in women and men with severe mental illness: prevalence and correlates. J. Trauma. Stress. 2001;14:615–632
  13. Goswami S, Mattoo SJ, Basu D, Singh G. Substance-abusing schizophrenics: do they self-medicate?. Am. J. Addict. 2004;13:139–150
  14. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J. Clin. Psychiatry. 2005;66:21–26
  15. Green AI, Strous RD, Zimmet SV, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv. Rev. Psychiatr. 1999;6:287–296
  16. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No. ADM 76-338). U.S. Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, pp. 218–222.
  17. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL, Davis JM, Lewis DA. Predicting the ‘revolving door’ phenomenon among patient with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry. 1995;151:856–861
  18. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800–802
  19. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743–755
  20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  21. Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 2003;29:45–55
  22. Keefe RSE, Bilder RM, Harvey PD, Davis S, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology. 2006;4:1–14
  23. Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer B, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 2007;64:633–647
  24. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry. 1997;54:313–321
  25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl. J. Med. 2005;353:1209–1223
  26. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J. Subst. Abuse Treat. 2001;21:217–221
  27. McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br. J. Psychiatry. 2002;181:321–325
  28. McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia: its relationship to acute psychopathology. J. Nerv. Ment. Dis. 1989;177:43–47
  29. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Rosenheck RA, Swartz MS, et al. Effectiveness of clozapine, quetiapine and risperidone in patients with chronic schizophrenia who failed prior atypical antipsychotic treatment. Am. J. Psychiatry. 2006;153:600–610
  30. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998;23:717–734
  31. Petrakis IL, Leslie D, Finney JW, Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am. J. Addict. 2006;15:44–49
  32. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J. Am. Med. Assoc. 1990;264:2511–2518
  33. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, Hepatitis B and Hepatitis C in people with severe mental illness. Am. J. Public Health. 2001;91:31–37
  34. Rosenheck R, Leslie D, Sindelar J, Miller EA, Stroup S, McEvoy J, et al. Cost-effectiveness of first and second generation antipsychotics in the treatment of chronic schizophrenia. Am. J. Psychiatry. 2006;163(12):2080–2089
  35. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res. 2001;48:109–123
  36. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can. J. Psychiatry. 2002;47:671–675
  37. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003;29:15–31
  38. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry. 2006;163:611–622
  39. Swanson J, Estroff S, Swartz M, Borum R, Lachicotte W, Zimmer C, et al. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry. 1997;60:1–22
  40. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am. J. Psychiatry. 1998;155:226–231
  41. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophr. Bull. 2003;29:33–43
  42. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J. Nerv. Ment. Dis. 2006;194:164–172
  43. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE Study. Psychiatr. Serv. 2006;57:1110–1116
  44. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am. J. Psychiatry. 2007;164(3):428–436
  45. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr. Res. 1996;20:145–151
  46. Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients?. J. Clin. Psychopharmacol. 2002;22:629–630

PII: S0920-9964(07)00542-7

doi: 10.1016/j.schres.2007.11.034

Schizophrenia Research
Volume 100, Issue 1 , Pages 39-52 , March 2008

Article Tools

* Image Usage & Resolution